跳至主要内容
临床试验/NCT07250867
NCT07250867尚未招募2 期

Safety and Efficacy of Lidocaine Versus Ketamine Infusion or Both Together as a Treatment Modality in Patient With Resistant Orofacial Pain; Double Blinded Randomized Study.

Assiut University0 个研究点目标入组 105 人开始时间: 2026年1月1日最近更新:
干预措施

试验速览

阶段
2 期
状态
尚未招募
入组人数
105
主要终点
Change in Visual Analog Scale (VAS) Pain Score

研究概览

简要总结

A prospective, randomized, double-blind clinical trial comparing the safety and efficacy of intravenous lidocaine, ketamine, and their combination as treatment options for patients suffering from treatment-resistant orofacial pain. The study measures pain reduction primarily using the Visual Analog Scale and evaluates safety and tolerability over a follow-up period of 6 months.

详细描述

This study aims to assess and compare the analgesic efficacy and safety profiles of intravenous lidocaine, ketamine, and a combined infusion of both in adult patients with orofacial pain that is resistant to conventional medical or interventional therapies. Using a randomized, double-blind design, 105 patients will be allocated equally into three parallel groups receiving either lidocaine infusion (5 mg/kg over 4 hours), ketamine infusion (0.3 mg/kg over 4 hours), or a combination infusion of lidocaine (2.5 mg/kg) and ketamine (0.15 mg/kg) over 3 consecutive weeks. Primary efficacy will be assessed by changes in pain intensity measured by the Visual Analog Scale (VAS) from baseline through follow-up visits at the 2nd and 3rd infusions, and 1, 3, and 6 months post-treatment. Secondary outcomes include cortisol level changes, depression assessment via PLAT-Q, and adverse events monitored during and after infusions. Strict inclusion and exclusion criteria will ensure patient safety and reliability of results. Data will be analyzed using one-way ANOVA and repeated measures ANOVA for continuous variables with significance set at p < 0.05.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • - Adults aged > 18 years
  • Resistant orofacial pain patients with failed medical or interventional treatment
  • Diagnosed with one or more of the following:
  • Trigeminal neuralgia
  • Temporomandibular joint (TMJ) dysfunction
  • Malignant otitis externa
  • Atypical facial pain

排除标准

  • - Debilitating cardiac disease
  • Uncontrolled hypertension
  • Known allergies to lidocaine or ketamine
  • Severe renal or hepatic impairment
  • Pregnancy or breastfeeding
  • History of substance abuse

研究组 & 干预措施

Lidocaine Infusion Group

Experimental

干预措施: Lidocaine Intravenous Infusion (Drug)

Ketamine Infusion Group

Experimental

干预措施: Ketamine intravenous infusion (Drug)

Lidocaine-Ketamine Combination Group

Experimental

干预措施: Combined lidocaine and ketamine intravenous infusion (Drug)

结局指标

主要结局

Change in Visual Analog Scale (VAS) Pain Score

时间窗: Baseline, prior to 2nd infusion, prior to 3rd infusion, 1 month, 3 months, and 6 months after intervention

Reduction in pain intensity as measured using the Visual Analog Scale (VAS), a 0-10 scale where 0 represents no pain and 10 represents the worst pain imaginable. The VAS will be assessed at baseline (before the first infusion) and at each follow-up visit (prior to 2nd infusion, prior to 3rd infusion, 1 month, 3 months, and 6 months after the intervention) to determine the effect of each treatment on resistant orofacial pain.

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Mohamed mustafa ahmed

Resident in Anesthesia, Intensive Care, and Pain Management Department, Faculty of Medicine, Assiut University.

Assiut University

相似试验